Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission
- B-cell Adult Acute Lymphoblastic Leukemia
- B Cell Chronic Lymphocytic Leukemia
- Hematopoietic/Lymphoid Cancer
- Refractory Chronic Lymphocytic Leukemia
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 5 years and 70 years
- Gender
- Both males and females
Description
Primary objectives To determine the safety and feasibility of allogeneic stem cell transplantation combined with adoptive transfer of T cells modified to express CD19-specific chimeric antigen receptor (CD19CAR) for treatment of leukemia and lymphoma Secondary objectives To measure the efficacy of t...
Primary objectives To determine the safety and feasibility of allogeneic stem cell transplantation combined with adoptive transfer of T cells modified to express CD19-specific chimeric antigen receptor (CD19CAR) for treatment of leukemia and lymphoma Secondary objectives To measure the efficacy of the CD19CAR T cell infusion combined with allogeneic stem cell transplantation
Tracking Information
- NCT #
- NCT03110640
- Collaborators
- Hrain Biotechnology Co., Ltd.
- Second Affiliated Hospital of Nanchang University
- Investigators
- Principal Investigator: Kang Yu, M.D. First Affiliated Hospital of Wenzhou Medical University
Get Well Soon